Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
1.
Am J Clin Nutr ; 94(5): 1171-81, 2011 Nov.
Article in English | MEDLINE | ID: mdl-21993434

ABSTRACT

BACKGROUND: Extracts from Hoodia gordonii have been shown to decrease food intakes and body weights in animals and were proposed as a food supplement or ingredient for weight management. OBJECTIVE: We assessed the safety and efficacy of a 15-d repeated consumption of H. gordonii purified extract (HgPE) relative to a placebo in humans. DESIGN: Healthy, overweight women, who were stratified by percentage body fat, received either HgPE (n = 25) or a placebo (n = 24) for 15 d. Subjects were resident in a clinic for a 4-d run-in period and a 15-d treatment period in which they received 2 servings/d of 1110 mg HgPE or a placebo formulated in a yogurt drink 1 h before breakfast and dinner. Subjects were otherwise allowed to eat ad libitum from standardized menus. RESULTS: There were no serious adverse events, but HgPE was less well tolerated than was the placebo because of episodes of nausea, emesis, and disturbances of skin sensation. Blood pressure, pulse, heart rate, bilirubin, and alkaline phosphatase showed significant (P < 0.05) increases in the HgPE group. Mean effects on ad libitum energy intakes and body weights did not differ significantly between the HgPE- and placebo-treatment groups (P > 0.05). CONCLUSIONS: In comparison with a matched placebo, the consumption of HgPE for 15 d appeared to be associated with significant adverse changes in some vital signs and laboratory parameters. HgPE was less well tolerated than was the placebo and did not show any significant effects on energy intakes or body weights relative to the placebo. This trial was registered at clinicaltrials.gov as NCT01306422.


Subject(s)
Apocynaceae/chemistry , Eating/drug effects , Overweight/drug therapy , Phytotherapy/methods , Plant Extracts/administration & dosage , Adolescent , Adult , Alkaline Phosphatase/blood , Bilirubin/blood , Blood Pressure/drug effects , Body Weight/drug effects , Double-Blind Method , Drug Administration Schedule , Female , Heart Rate/drug effects , Humans , Middle Aged , Overweight/metabolism , Overweight/physiopathology , Phytotherapy/adverse effects , Plant Extracts/adverse effects , Plant Extracts/pharmacokinetics , Young Adult
2.
Regul Toxicol Pharmacol ; 59(1): 19-27, 2011 Feb.
Article in English | MEDLINE | ID: mdl-21156195

ABSTRACT

Callithrix jacchus (common marmoset) is one of the more primitive non-human primate species and is used widely in fundamental biology, pharmacology and toxicology studies. Marmosets breed well in captivity with good reproductive efficiencies and their sexual maturity is reached within 18 months of age allowing for rapid expansion of colonies and early availability of sexually mature animals permitting an earlier assessment of product candidates in the adult. Their relatively small size allows a reduction in material requirements leading to a reduction in development time and cost. Fewer animals are also required due to their ability to be used in both pharmacology and toxicology (nonclinical) studies. These factors, alongside a better understanding of their optimal nutrient and welfare requirements over recent years, facilitate the generation of a more cohesive and robust dataset. With the growth of biotechnology-derived pharmaceuticals, non-human primate use has, by necessity, also increased; nevertheless, there is also a growing public call for minimizing their use. Utilizing, the more primitive marmoset species may provide the optimal compromise and once the scientific rationale has been carefully considered and their use justified, there are several advantages to using the marmoset as a model in nonclinical development of pharmaceutical products.


Subject(s)
Callithrix/physiology , Pharmaceutical Preparations , Pharmacokinetics , Toxicity Tests , Animal Husbandry , Animals , Body Size , Drug-Related Side Effects and Adverse Reactions , Female , Male , Models, Animal , Pharmaceutical Preparations/chemistry , Pharmaceutical Preparations/metabolism , Reproducibility of Results , Species Specificity
3.
Neurobiol Aging ; 31(6): 1010-9, 2010 Jun.
Article in English | MEDLINE | ID: mdl-18676061

ABSTRACT

The purpose of this work is to study the effect of smilagenin on the mRNA stability of muscarinic receptor subtype 1 (M(1); m1 mRNA) in aged rat brains and its significance in improving memory. The Y-maze avoidance task showed that oral administration of smilagenin significantly improved spatial memory performance in aged rats. Mechanistic studies showed that smilagenin was neither a ligand of the M receptors nor a cholinesterase inhibitor, while radioligand binding assays revealed that smilagenin significantly increased the M(1)-receptor density. The increase of M(1)-receptor density correlated with memory improvement. Real-time polymerase chain reaction (RT-PCR) revealed that the m1 mRNA in m1 gene-transfected CHO cells increased significantly, and the average half-life of m1 mRNA was approximately doubled by smilagenin treatment. These results suggest that smilagenin improves memory of aged rats at least partially by increasing the stability of m1 mRNA. However since the ChAT activity in the cortex of aged rats was also elevated by smilagenin, it cannot be excluded that the increase of intrinsic acetylcholine excretion also plays a role in the memory-improvement effect of smilagenin.


Subject(s)
Aging , Gene Expression Regulation/drug effects , Memory Disorders/drug therapy , RNA, Messenger/metabolism , Receptor, Muscarinic M1/genetics , Spirostans/therapeutic use , 3,3'-Diaminobenzidine/pharmacokinetics , Analysis of Variance , Animals , Atropine/pharmacology , Binding Sites/drug effects , Binding, Competitive/drug effects , Brain/drug effects , Brain/metabolism , CHO Cells , Cholinesterase Inhibitors/pharmacology , Cholinesterases/metabolism , Cricetinae , Cricetulus , Disease Models, Animal , Dose-Response Relationship, Drug , Maze Learning/drug effects , Maze Learning/physiology , Memory Disorders/pathology , Muscarinic Antagonists/pharmacology , Rats , Rats, Sprague-Dawley , Receptor, Muscarinic M1/metabolism , Tacrine/pharmacology , Transfection/methods , Tritium/pharmacokinetics
4.
FASEB J ; 22(7): 2488-97, 2008 Jul.
Article in English | MEDLINE | ID: mdl-18364399

ABSTRACT

Many experimental data support the enhancement of neurotrophic factors as a means to modify neurodegeneration in Parkinson's disease. However, the translation of this to the clinic has proven problematic. This is likely due to the complex nature of the surgical gene delivery and cell-based approaches adopted to deliver proteinaceous neurotrophic factors to targets within the central nervous system. We investigated the ability of a novel, orally active, nonpeptide neurotrophic factor inducer, PYM50028 (Cogane), to restore dopaminergic function after 1-methyl-4-phenylpyridinium (MPP(+)) -induced damage to mesencephalic neurons in vitro and in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) -lesioned mice. In rat mesencephalic neurons, administration of PYM50028, either before or after MPP(+), significantly prevented and reversed both MPP(+)-induced neuronal atrophy and cell loss. These effects were potent and of a magnitude equivalent to those achieved by a combination of brain-derived neurotrophic factor (BDNF) and glial-derived neurotrophic factor (GDNF). Oral administration of PYM50028 (10 mg/kg/day for 60 days) to MPTP-lesioned mice, commencing after a striatal impairment was evident, resulted in a significant elevation of striatal GDNF (297%) and BDNF (511%), and attenuated the loss of striatal dopaminergic transporter levels and dopaminergic neurons in the substantia nigra. PYM50028 did not inhibit monoamine oxidase B in vitro, nor did it alter brain levels of MPP(+) in vivo. PYM50028 has neuroprotective and neurorestorative potential and is in clinical development for the treatment of neurodegenerative disorders, including Parkinson's disease.


Subject(s)
Mesencephalon/pathology , Nerve Growth Factors/therapeutic use , Neurons/pathology , Parkinsonian Disorders/chemically induced , Parkinsonian Disorders/prevention & control , Spirostans/therapeutic use , 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine/pharmacology , Administration, Oral , Animals , Disease Models, Animal , Glial Cell Line-Derived Neurotrophic Factor/pharmacology , Male , Mesencephalon/drug effects , Mice , Nerve Growth Factors/administration & dosage , Neurons/drug effects , Neurotoxins/toxicity , Rats , Tyrosine 3-Monooxygenase/drug effects , Tyrosine 3-Monooxygenase/metabolism
5.
FEBS Lett ; 582(6): 956-60, 2008 Mar 19.
Article in English | MEDLINE | ID: mdl-18298955

ABSTRACT

Tyrosine hydroxylase immunohistochemical analysis revealed that in cultured mesencephalic dopaminergic neurons smilagenin (SMI), added prior to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPP+), protected against the drop of neuron number and neurite outgrowth length caused by MPP+. Addition of anti-GDNF and/or anti-GFR alpha 1 functional antibodies to the medium prior to SMI, eliminated mostly, though incompletely, the action of SMI. The expression of glial cell derived neurotrophic factor (GDNF) mRNA, but not GDNF receptor alpha1 (GFR alpha 1) or receptor tyrosine kinase mRNA in MPP+ intoxicated neurons was markedly elevated as early as 2h after the addition of SMI with a peak at 24-48 h. Therefore, an important route of the protective action of SMI on dopaminergic neurons is to stimulate intrinsic GDNF expression.


Subject(s)
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine/antagonists & inhibitors , Glial Cell Line-Derived Neurotrophic Factor/metabolism , Mesencephalon/drug effects , Neurons/drug effects , Spirostans/pharmacology , 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine/pharmacology , Animals , Cytoprotection , Dopamine/metabolism , Dopamine Agents/pharmacology , Female , Glial Cell Line-Derived Neurotrophic Factor/genetics , Glial Cell Line-Derived Neurotrophic Factor Receptors/genetics , Glial Cell Line-Derived Neurotrophic Factor Receptors/metabolism , Mesencephalon/cytology , Mesencephalon/metabolism , Neurons/metabolism , Rats , Rats, Sprague-Dawley , Receptor Protein-Tyrosine Kinases/genetics , Receptor Protein-Tyrosine Kinases/metabolism , Tyrosine 3-Monooxygenase/analysis , Tyrosine 3-Monooxygenase/metabolism
6.
Brain Res ; 1060(1-2): 26-39, 2005 Oct 26.
Article in English | MEDLINE | ID: mdl-16226729

ABSTRACT

The purpose of this paper is to study the basic pharmacological action of sarsasapogenin, a sapogenin from the Chinese medicinal herb Rhizoma Anemarrhenae, (abbreviated as ZMS in this paper), on learning ability and memory of three animal models: aged rats and two neurodegeneration models produced either by single unilateral injection of beta-amyloid 1-40 (Abeta1-40) plus ibotenic acid (Ibot A) or by bilateral injection of Ibot A alone into nucleus basalis magnocellularis. Y-maze test and step-through test revealed that learning ability and memory were impaired in the three models and were improved by oral administration of ZMS. ZMS did not inhibit acetylcholinesterase nor did it occupy the binding sites of muscarinic acetylcholine receptor (M receptor), hence it is neither an cholinesterase inhibitor nor an agonist or antagonist of M receptors. On the other hand, the densities of total M receptor and its M1 subtype in the brain of the three models were significantly lower than control rats, and ZMS significantly raised the densities of total M receptors and its M1 subtype. Linear regression revealed significant correlation between the learning ability/memory and the density of either total M receptor or its M1 subtype. Autoradiographic study with 3H-pirenzipine showed that the M1 subtype density was significantly lowered in cortex, hippocampus and striatum of aged rats, and ZMS could reverse these changes towards normal control level. Interestingly, the M1 receptor density after ZMS administration only approached but did not exceed that of normal young control rats. Therefore, ZMS seems to represent a new approach to the pharmacological regulation of learning and memory and appears to be not simply palliative but may modify the progression of the disease.


Subject(s)
Brain/drug effects , Memory Disorders/drug therapy , Receptors, Muscarinic/drug effects , Spirostans/pharmacology , Acetylcholinesterase/drug effects , Acetylcholinesterase/metabolism , Age Factors , Amyloid beta-Peptides/toxicity , Animals , Autoradiography , Disease Models, Animal , Excitatory Amino Acid Agonists/toxicity , Female , Ibotenic Acid/toxicity , Immunohistochemistry , Male , Maze Learning/drug effects , Memory Disorders/chemically induced , Nerve Degeneration/chemically induced , Neurotoxins/pharmacology , Peptide Fragments/toxicity , Rats , Rats, Sprague-Dawley
SELECTION OF CITATIONS
SEARCH DETAIL
...